2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Indoleamine 2,3-Dioxygenase (IDO)

Indoleamine 2,3-Dioxygenase (IDO)

Indoleamine 2,3-Dioxygenase (IDO)

Related Products

PDF 0.8 MB

Indoleamine 2, 3-dioxygenase (IDO) is an inflammatory cytokine-inducible rate-limiting enzyme of the tryptophan (Trp) catabolism, which is involved in the inhibition of intracellular pathogen replication as well as in immunomodulation. To date, three types of tryptophan-metabolizing enzymes have been identified: IDO1, IDO2 and tryptophan 2,3-dioxygenase 2.

IDO is an intracellular enzyme that is constitutively expressed in several human and mouse cells. Being present in innate immune cells, such as Mos and dendritic cells (DCs), IDO catalyzes the initial rate-limiting step of tryptophan (Trp) catabolism, thus leading to the production of immunoregulatory catabolites (collectively known as kynurenines).

The IDO gene promoter contains multiple sequence elements that confer responsiveness to proinflammatory mediators, thereby demonstrating the strong correlation between inflammation and induced IDO expression.

Indoleamine 2,3-Dioxygenase (IDO) Isoform Specific Products:

Indoleamine 2,3-Dioxygenase (IDO) Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-111234
    IDO-IN-11
    		Inhibitor
    IDO-IN-11 is an indoleamine-2,3-dioxygenase (IDO) inhibitor with IC50s of 0.18 μM (Kinase) and 0.014 μM (Hela Cell), extracted from patent WO 2016041489 A1, compound 13.
    IDO-IN-11
  • HY-145280A
    IDO1/2-IN-1 hydrochloride
    		Inhibitor
    IDO1/2-IN-1 hydrochloride (compound 4t) is the first potent IDO1/IDO2 dual inhibitor with IC50s of 28 nM and 144 nM for IDO1 and IDO2, respectively. IDO1/2-IN-1 hydrochloride exhibits antitumor activies. Orally active.
    IDO1/2-IN-1 hydrochloride
  • HY-151978
    ZC0109
    		Inhibitor 99.32%
    ZC0109 is a dual inhibitor of IDO1 and thioredoxin reductase 1 (TrxR1) with IC50s of 50 nM and 3.0 μM, respectively. ZC0109 induces ROS accumulation and cell cycle arrest at G1/S phase, thus leads to cancer cells apoptosis.
    ZC0109
  • HY-148173
    NUCC-0223619
    		Inhibitor
    NUCC-0223619 is an IDO1 inhibitor, induce degradation of IDO protein. NUCC-0223619 can be used to synthesis PROTAC.
    NUCC-0223619
  • HY-144468
    IDO1-IN-17
    		Inhibitor
    IDO1-IN-17 (I-4) is an IDO1 inhibitor, with an IC50 of 0.44 μM in hela cells.
    IDO1-IN-17
  • HY-146674
    IDO1/TDO-IN-3
    		Inhibitor
    IDO1/TDO-IN-3 is a potent inhibitor of IDO1/TDO. IDO1/TDO-IN-3 exhibits significant activities against IDO1 (IC50: 0.005 μM) and TDO (IC50: 0.004 μM). IDO1/TDO-IN-3 shows considerable in vivo anti-tumor activity and no obvious toxicity is observed.
    IDO1/TDO-IN-3
  • HY-172453
    XW-032
    		Inhibitor
    XW-032 is an apo-IDO1 inhibitor, with an IC50 of 21 nM. XW-032 (TGI = 63%) exhibits potent in vivo anti-tumor efficacy in the CT26 syngeneic mouse model and is expected to be applied in the research of the field of cancer.
    XW-032
  • HY-162962
    IDO1/TDO-IN-7
    		Inhibitor
    IDO1/TDO-IN-7 (Compound 43b), an isoquinoline derivative, is a potent dual IDO1/TDO inhibitor, with IC50s of 0.31 μM and 0.08 μM, respectively. IDO1/TDO-IN-7 displays acceptable pharmacokinetic profiles and potent antitumor efficacy with low toxicity in B16-F10 tumor model.
    IDO1/TDO-IN-7
  • HY-139883
    IDO-IN-15
    		Inhibitor
    IDO-IN-15 is an IDO1 inhibitor (IC50 < 0.51 nM).
    IDO-IN-15
  • HY-N0353R
    Curdione (Standard)
    Curdione (Standard) is the analytical standard of Curdione. This product is intended for research and analytical applications. Curdione ((+)-Curdione) is an orally active sesquiterpenoid. Curdione inhibits platelet aggregation. Curdione induces ferroptosis in colorectal cancer via m6A methylation mediated by METTL14 and YTHDF2. Curdione inhibits ferroptosis in Isoproterenol (HY-B0468)-induced myocardial infarction by regulating the Keap1/Trx1/GPX4 signaling pathway, suppressing oxidative stress (ROS) and apoptosis. Curdione ameliorates Doxorubicin (HY-15142)-induced cardiotoxicity by inhibiting oxidative stress (ROS) and activating the Nrf2/HO-1 pathway. Curdione ameliorates sepsis-induced lung injury by inhibiting platelet-mediated neutrophil extracellular trap formation. Curdione ameliorates Bleomycin (HY-17565A)-induced pulmonary fibrosis by inhibiting TGF-β-induced fibroblast-to-myofibroblast differentiation. Curdione exhibits neuroprotective effects against focal cerebral ischemia-reperfusion injury in rats. Curdione exerts antiproliferative effects against human uterine leiomyosarcoma by targeting IDO1. Curdione protects vascular endothelial cells and atherosclerosis by regulating DNMT1-mediated ERBB4 promoter methylation. Curdione inhibits inducible prostaglandin E2 production (IC50 = 1.1 μM) and cyclooxygenase 2 expression.
    Curdione (Standard)
  • HY-147772
    ZC0101
    		Inhibitor
    ZC0101 is a potent, orally active IDO1 and TrxR dual inhibitor with IC50 values of 0.084 μM and 7.98 μM, respectively. ZC0101 effectively induces apoptosis and ROS accumulation in cancer cells.
    ZC0101
  • HY-173066
    NU227326
    		Degrader
    NU227326 is the PROTAC degrader for Indoleamine 2,3-dioxygenase 1 (IDO1) with DC50 of 4.5 nM. NU227326 degrades IDO1 in cell U87 and GBM43 with DC50 of 7.1 nM and 11.8 nM. NU227326 exhibits good pharmacokinetic properties with a plasma half-life of 5.7 hours and a brain tissue half-life of 11.8 hours.(Pink: ligand for target protein IDO1 ligand-1 (HY-173067); Black: linker (HY-173068); Blue: ligand for E3 ligase Cereblon (HY-W087383))
    NU227326
  • HY-120742
    MMG-0358
    		Inhibitor
    MMG-0358 is a potent IDO1 inhibitor. MMG-0358 shows IC50 values of 2 nM in a cellular assay on mIDO1, 80 nM in a cellular assay on hIDO1, 330 nM in an enzymatic assay on hIDO1 at pH 6.5, and 71 nM in an enzymatic assay on hIDO1 at pH 7.4.
    MMG-0358
  • HY-112164A
    IACS-8968 R-enantiomer
    		Inhibitor 98.48%
    IACS-8968 (R-enantiomer) is the R-enantiomer of IACS-8968. IACS-8968 is a dual IDO and TDO inhibitor, with pIC50s of 6.43 for IDO and <5 for TDO, respectively.
    IACS-8968 R-enantiomer
  • HY-113568
    CAY10581
    		Inhibitor
    CAY10581, a pyranonaphthoquinone derivative, is a highly specific and reversible uncompetitive IDO Inhibitor with an IC50 of 55 nM.
    CAY10581
  • HY-161996
    IDO1-IN-25
    		Inhibitor
    IDO1-IN-25 is a dual inhibitor of IDO1/TDO2, with IC50 values of 0.17 μM and 3.2 μM, respectively. IDO1-IN-25 can effectively inhibit the production of NO in RAW264.7 cells stimulated by lipopolysaccharide (LPS). IDO1-IN-25 can exert anti-inflammatory effects in a mouse ear edema acute inflammation model induced by croton oil.
    IDO1-IN-25
  • HY-178024
    IDO1-IN-29
    		Inhibitor
    IDO1-IN-29 (Compound MQ-1n) is a Apo-IDO1 inhibitor with an IC50 of 0.29  μM. IDO1-IN-29 selectively targets apo-IDO1 and disrupts heme binding. IDO1-IN-29 can be used for cancers research.
    IDO1-IN-29
  • HY-160025
    IDO antagonist-1
    		Antagonist
    IDO antagonist-1 (compound 163) is an antagonist of IDO . IDO antagonist-1 inhibits pancreatic adenocarcinoma cells growth in C57BL/6 mice.
    IDO antagonist-1
  • HY-156400
    IDO1-IN-23
    		Inhibitor
    IDO1-IN-23 (compound 41) is a potent human IDO1 inhibitor with an IC50 value of 13 μM.
    IDO1-IN-23
  • HY-D0033
    Roxyl-9
    		Inhibitor 99.22%
    Roxyl-9 is a IDO1 (Indoleamine 2,3-dioxygenase 1) inhibitor.
    Roxyl-9
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity
Indoleamine 2,3-Dioxygenase (IDO) Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.